Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hemarus is a healthcare company focused on human plasma collection and plasma-derived biopharmaceuticals. In the United States, Hemarus operates FDA-licensed plasma donation centers that collect source plasma used to manufacture therapies for patients with rare diseases, immune deficiencies, hemophilia, trauma-related conditions, and other blood disorders. The name is also associated with Hemarus Therapeutics Limited in India, which has been described as a manufacturer of plasma-derived products including immunoglobulins, critical-care products, hemophilia-related therapies, and wound-healing products. Publicly available information suggests the business has both donor-center operations and historical or affiliated plasma-fractionation product development activity. Overall, Hemarus appears to be a niche plasma-focused healthcare company rather than a traditional venture-backed drug developer with a disclosed clinical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hemarus.